Ossium Health Stock

www.ossiumhealth.com/Healthcare / BioTech & PharmaFounded: 2016Funding to Date: $124.87MM

Ossium Health is a bioengineering stem-cell research company. With a mission to treat diseases such as leukemia or radiation poisoning, Ossium Health uses its understanding of biology to improve the health and longevity of its patients. Additionally, the company has a specialization in Cryopreservation, bone marrow banking, stem cell transplants, and bone marrow transplants. Ossium Health was founded by Dr. Sebastian Eriksson Giwa, Erik Woods, and Kevin Caldwell in 2016 and is headquartered in San Francisco, CA.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for Ossium Health, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Ossium Health Stock Price

Forge Price 1
Price no longer available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Ossium Health Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
07/25/2023 Series C $50.72MM $xx.xx $308.87MM Alumni Ventures, Asahi Kasei, Cpmg, First Round Capital, Manta Ray Venures, Vivo Capital
Price per Share
$xx.xx
Shares Outstanding
133,514,438
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
10.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Alumni Ventures, Asahi Kasei, Cpmg, First Round Capital, Manta Ray Venures, Vivo Capital
03/10/2021 Series B-3 $174,999.93 $xx.xx $233.96MM First Round Capital, General Catalyst, Manta Ray Ventures, Vivo Capital, Xyz Capital
Price per Share
$xx.xx
Shares Outstanding
862,494
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
First Round Capital, General Catalyst, Manta Ray Ventures, Vivo Capital, Xyz Capital
03/10/2021 Series B-3 Prime $174,999.93 $xx.xx $233.96MM First Round Capital, General Catalyst, Manta Ray Ventures, Vivo Capital, Xyz Capital
Price per Share
$xx.xx
Shares Outstanding
862,494
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
First Round Capital, General Catalyst, Manta Ray Ventures, Vivo Capital, Xyz Capital
03/10/2021 Series B-2 $2.7MM $xx.xx $233.96MM First Round Capital, General Catalyst, Manta Ray Ventures, Vivo Capital, Xyz Capital
Price per Share
$xx.xx
Shares Outstanding
10,892,082
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
First Round Capital, General Catalyst, Manta Ray Ventures, Vivo Capital, Xyz Capital
03/10/2021 Series B-2 Prime $2.7MM $xx.xx $233.96MM First Round Capital, General Catalyst, Manta Ray Ventures, Vivo Capital, Xyz Capital
Price per Share
$xx.xx
Shares Outstanding
10,892,082
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
First Round Capital, General Catalyst, Manta Ray Ventures, Vivo Capital, Xyz Capital
03/10/2021 Series B-1 Prime $3.84MM $xx.xx $233.96MM First Round Capital, General Catalyst, Manta Ray Ventures, Vivo Capital, Xyz Capital
Price per Share
$xx.xx
Shares Outstanding
17,301,077
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
First Round Capital, General Catalyst, Manta Ray Ventures, Vivo Capital, Xyz Capital
03/10/2021 Series B-1 $3.84MM $xx.xx $233.96MM First Round Capital, General Catalyst, Manta Ray Ventures, Vivo Capital, Xyz Capital
Price per Share
$xx.xx
Shares Outstanding
17,301,077
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
First Round Capital, General Catalyst, Manta Ray Ventures, Vivo Capital, Xyz Capital
03/10/2021 Series B Prime $25MM $xx.xx $233.96MM First Round Capital, General Catalyst, Manta Ray Ventures, Vivo Capital, Xyz Capital
Price per Share
$xx.xx
Shares Outstanding
77,519,377
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
First Round Capital, General Catalyst, Manta Ray Ventures, Vivo Capital, Xyz Capital
03/10/2021 Series B $25MM $xx.xx $233.96MM First Round Capital, General Catalyst, Manta Ray Ventures, Vivo Capital, Xyz Capital
Price per Share
$xx.xx
Shares Outstanding
77,519,377
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
First Round Capital, General Catalyst, Manta Ray Ventures, Vivo Capital, Xyz Capital
05/14/2018 Series A-2 $388,592.99 $xx.xx $42.95MM Gaingels
Price per Share
$xx.xx
Shares Outstanding
3,475,787
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Gaingels
05/14/2018 Series A-2 Prime $388,592.99 $xx.xx $42.95MM Gaingels
Price per Share
$xx.xx
Shares Outstanding
3,475,787
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Gaingels
05/14/2018 Series A-1 $475,276.95 $xx.xx $42.95MM Gaingels
Price per Share
$xx.xx
Shares Outstanding
8,744,746
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Gaingels
05/14/2018 Series A-1 Prime $475,276.95 $xx.xx $42.95MM Gaingels
Price per Share
$xx.xx
Shares Outstanding
8,744,746
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Gaingels
05/14/2018 Series A-3 Prime $1.08MM $xx.xx $42.95MM Gaingels
Price per Share
$xx.xx
Shares Outstanding
10,965,039
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Gaingels
05/14/2018 Series A-3 $1.08MM $xx.xx $42.95MM Gaingels
Price per Share
$xx.xx
Shares Outstanding
10,965,039
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Gaingels
05/14/2018 Series A $3.42MM $xx.xx $42.95MM Gaingels
Price per Share
$xx.xx
Shares Outstanding
15,330,761
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Gaingels
05/14/2018 Series A Prime $3.42MM $xx.xx $42.95MM Gaingels
Price per Share
$xx.xx
Shares Outstanding
15,330,761
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Gaingels

Ossium Health Investors Also Invested in These Private Companies

Leadership & Board

Leadership

Kevin Caldwell ESQ
Co-Founder, Chief Executive Officer & President
Erik Woods Ph.D
Co-Founder, Chief Scientific Officer, Executive Vice President of Clinical Laboratory Improvement Amendments & Laboratory Director
Sagar Munjal MD
Chief Medical Officer & Senior Vice President
Margie Mathewson Ph.D
Senior Vice President of Business Operations
Brian Johnstone Ph.D
Vice President of Research

Board

Bill Trenchard
First Round Capital
Edgar Engleman MD
Vivo Capital

Ossium Health stock FAQs

plusminus

Can you buy Ossium Health stock?

As Ossium Health is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Ossium Health, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy Ossium Health stock?

To invest in a private company like Ossium Health through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Ossium Health stock?

Yes, you may sell the Ossium Health stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Ossium Health stock?

If you hold private company shares of Ossium Health – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Ossium Health on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Ossium Health a public company?

No, Ossium Health is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Ossium Health’s stock price?

Ossium Health is a privately held company and therefore does not have a public stock price. However, you may access Ossium Health private market stock price with Forge Data.
plusminus

What is Ossium Health’s stock ticker symbol?

Ossium Health does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Ossium Health’s News and Media Highlights

Bioengineering company Ossium Health has secured $52m in Series C funding for expanding its bone marrow stem cell bank. The funding will also be utilised by the company to advance its cell therapy clinical trials intended for the treatment of blood and immune diseases.
Updated on: Nov 22, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.